BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 1324553)

  • 21. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives.
    Hamerlynck JV; Vollebregt JA; Doornebos CM; Muntendam P
    Contraception; 1987 Mar; 35(3):199-205. PubMed ID: 2956054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel.
    Rekers H
    Acta Obstet Gynecol Scand; 1988; 67(2):171-4. PubMed ID: 2972160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with triphasic oral contraceptive (Triquilar) in 527 women in China.
    Weng LJ; Xu D; Zheng HZ; Zhang JY; Sang GW; Qian LJ
    Contraception; 1991 Mar; 43(3):263-71. PubMed ID: 2036797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norgestimate: a clinical overview of a new progestin.
    Bringer J
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with a triphasic oral contraceptive.
    Ulstein M; Svendsen E; Steier A; Bratt H; Fylling P; Lie S; Schiefloe A; Aaserud J
    Acta Obstet Gynecol Scand; 1984; 63(3):233-6. PubMed ID: 6428157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet).
    Kornaat H; Geerdink MH; Klitsie JW
    Contraception; 1992 Feb; 45(2):119-27. PubMed ID: 1559335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term experience with a low-dose oral contraceptive.
    Brill K; Schnitker J; Albring M
    Gynecol Endocrinol; 1990 Dec; 4(4):277-86. PubMed ID: 2150581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
    Anderson FD
    Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
    Weber-Diehl F; Lehnert J; Lachnit U
    Contraception; 1993 Oct; 48(4):291-301. PubMed ID: 8222658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with a low dose oral contraceptive containing norethisterone and ethinyl oestradiol.
    Morigi EM; Pasquale SA
    Curr Med Res Opin; 1978; 5(8):655-62. PubMed ID: 710178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progestogen-only microdose followed by estrogen-progestogen combination, a new approach to oral contraception.
    Russowsky M; Sartoretto JN
    Contraception; 1982 Jul; 26(1):41-9. PubMed ID: 7128133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined hormonal contraception in cycles artificially extended].
    Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
    Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.